

Charles Wadley Duckworth, MD

Certification and Licensure

Georgia State Medical License
South Carolina Medical License
Virginia Medical License
American Board of Internal Medicine
American Board of Internal Medicine

Professional Societies

American Society for Gastrointestinal Endoscopy
American Gastroenterological Association
American College of Gastroenterology

Education

1981-1985 University of Georgia, Athens, GA
 B.S. in Microbiology awarded June 1985

1986-1990 Medical College of Georgia, Augusta, GA
 Doctor of Medicine awarded June 1990

1990-1993 University of Virginia, Charlottesville, VA
 Residency, Internal Medicine

1993-1996 University of Virginia, Charlottesville, VA
 Fellowship, Gastroenterology

Honors/Awards

Alpha Omega Alpha Honor Society
Phi Kappa Phi Honor Society
Phi Beta Kappa Honor Society
Gold Key Honor Society

Professional Experience

June 1994 – Present Medical College of Georgia, Augusta, GA
 Department of Medicine, Clinical Assistant Professor

July 1996-Feb 1999 Emory University School of Medicine, Atlanta, GA
 Department of Internal Medicine, Assistant Professor

Employment Experience

Jan 2001 – Present The Center for Digestive and Liver Health, Savannah, GA
 Gastroenterologist/Hepatologist

Feb 1999-Dec 2000 Savannah Center for Digestive and Liver Diseases, Savannah, GA
Gastroenterologist/Hepatologist

June 1999 – Present Southeastern Digestive and Liver Disease Institute, Savannah, GA
Investigator

Feb 1999 – Dec 2000 Memorial Health University Medical Center, Savannah, GA
Attending Physician

PUBLICATIONS

Manuscripts

Duckworth CW, Fisher JF, Carter SA, Newman CL, Cogburn C, Nesbit RR, Wray CH. Tissue penetration of clindamycin in diabetic foot infections. *J Antimicrobial Chemotherapy* 1993; 31:581-84.

Duckworth CW, Peura D. Helicobacter pylori and GI disease: What critical care physicians need to know. *J Crit Illness* 1995; 10(22):105-117.

Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically ill patients. *Am J Gastroenterol* 1997; 92(1):79-83.

Kiss R, Camby I, Duckworth C, De Decker R, Salmon I, Pasteels J-L, Danguy A, Yeaton P. In vitro influence of Phaseolus vulgaris, Griffonia simplicifolia, concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth. *Gut* 1997;40:253-261.

Duckworth C, Kolar B, Yoshida C, Slingluff C. Mesenteric tumor emboli manifested as recurrent abdominal pain. *South Med J* 1997;90(4):419-422.

Sears RJ, Duckworth CW, Decaestecker C, Bourgeois N, Ledent T, Deviere J, Salmon I, Kiss R, Yeaton P. Image cytometry as a discriminatory tool for cytologic specimens obtained by endoscopic retrograde cholangiopancreatography. *Cancer (Cancer Cytopathol)* 1998;84:119-26.

Yeaton P, Frierson HF, Hittelet A, Duckworth C, DePrez C, Bourgeois N, Salmon I, Jones RS, Kiss R, Decaestecker C. Use of image cytometry to classify biliary and ampullary adenocarcinomas. *Anal Quan Cyto Histo* 1998;20:509-516.

Book Chapters

Duckworth CW, Kiss R, Yeaton P. Endoscopy in Pancreatic Disease, Mosby-Wolfe 1997, pp37-46.

Abstracts

Soroka S, Duckworth C. Is this a spirochete gastroenterologists should worry about? *Am J Gastroenterol* 1998;93(9):1744.

Duckworth C, Kolar BJ, Yoshida C, Slingluff C. Mesenteric tumor emboli presenting as recurrent abdominal pain. Accepted as a poster presentation, American College of Gastroenterology Meeting, Sept 1994.

Duckworth C, Locke C, Peura D. ¹⁴C breath testing for H.pylori in the fasting and non fasting state. *Gastroenterology* 1995;108(4):A85.

Yeaton P, Frierson HF, Duckworth C, Salmon I, Pasteels JL, Jones RS, Kiss R. Use of image cytometry to create an expert system to classify biliary and ampullary adenocarcinomas. *Gastroenterology* 1995;108(4):A556.

Duckworth C, Salmon I, Yeaton P, Kiss R. Quantitative assessment of PNA and CEA staining in colorectal adenocarcinoma. *Am J Gastroenterol* 1995;90(9):1640.

Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in ICU patients. *Am J Gastroenterol* 1995;90(9):1575.

Sears RJ, Duckworth CW, Balaban DH, Han K, Goldin G, Oelsner DH, Yeaton P. Erythromycin vs. gastric lavage for pre-endoscopic preparation of patients with upper gastrointestinal bleeding. *Gastrointestinal Endo* 1996;43(4):358.

Burney J, Duckworth C. Are current colon cancer screening guidelines appropriate for African Americans? *Am J Gastroenterol* 1997;92(9):1671.

Diamonti G, Duckworth C, Carey J, Lim K. The etiology of iron deficiency anemia in African-Americans. *Gastroenterol* 1999;116(4):A55.

Fukushima T, Duckworth C. Helicobacter prevalence in African-Americans with peptic ulcer disease. (Accepted for Gastro 99).

Clinical Trials

Sep 1998 – Present	Sub-Investigator, “Intron A + Ribavirin + Amantadine versus Intron A + Ribavirin for Treatment of Patients with Chronic Hepatitis C not Previously Treated with Interferon: a Randomized Trial.” Schering Integrated Therapeutics, unrestricted grant.
May 1999 – Jul 2000	Sub-Investigator, “Efficacy of Infergen for Hepatitis C in Patients Who are Non-Responders to Combination Therapy with Intron A + Ribavirin. A Multi-center Trial.” Amgen, Inc. Protocol 980170.
Jul 1999 – Apr 2001	Sub-Investigator, “A Randomized, Double-Masked, Placebo-Controlled Study of Subcutaneously Administered

Recombinant Human Interleukin-11 (rhIL-11) in Patients with Active Crohn's Disease not treated with Prednisone." Genetics Protocol C9853-14.

Dec 1999 – Oct 2000

Sub-Investigator, "A 24 Week Randomized, Open Label Study of Health Care Resource Use, Quality of Life and Productivity with Alosetron 1 mg Twice Daily versus traditional Therapy in Females with Diarrhea Predominant Irritable Bowel Syndrome." GlaxoWellcome Protocol S3B30020.

Jul 2000 – Dec 2000

Sub-Investigator, "Comparative Efficacy Study of Esomeprazole Magnesium (40mg qd) and Lansoprazole (30mg qd) in Patients with Erosive Esophagitis." AstraZeneca Protocol 267.

Apr 2000 – Present

Sub-Investigator, "Prevention of Sporadic Colorectal Adenomas with Celecoxib." Kendle Searle Protocol IQ4-99-02-005. In conjunction with the national Cancer Institute Protocol No-1CN-95015.

April 2001 – Present

Sub-Investigator, "Comparison of PEG Interferon alfa-2b plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects." Schering-Plough Integrated Therapeutics.